SiTime Corporation vs TransMedics Group Inc — how do they compare? SiTime Corporation trades at $587 (market cap $17.74B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: SiTime Corporation is far larger — about 5.9× TransMedics Group Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SITM | TMDX | |
|---|---|---|
Market Cap | $17.74B | $3.00B |
Sector | Technology | Technology |
52-Week High | $901.60 | $150.42 |
52-Week Low | $245.57 | $61.99 |
Enterprise Value | $17.14B | $3.39B |
Signals from Pluang's Aura AI — not financial advice
SITM trades at $598.95, down 2.15% today, but maintains strong analyst support with 9 unanimous buy ratings and a $863.33 consensus price target representing 44% upside. The stock shows bullish technical signals despite recent weakness, with support at $584 and resistance at $627. Recent Q2 2026 earnings beat expectations with $2.34 EPS versus $1.95 expected, driven by 127% revenue growth and AI infrastructure demand.
The outlook remains positive with Q3 2026 guidance pointing to substantial growth following the Renesas acquisition. Key risks include high valuation multiples (P/E 999, P/S 34) and negative 2025 net income, though 2026 projections show profitability improvement. Institutional buying, including California State Teachers' 73,098.9% stake increase, supports the growth narrative.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Trailing returns across standard periods
Latest headlines on both assets
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →